SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-16-760234
Filing Date
2016-11-04
Accepted
2016-11-04 16:33:04
Documents
8
Period of Report
2016-12-15
Effectiveness Date
2016-11-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A d268475ddef14a.htm DEF 14A 351785
2 GRAPHIC g268475g06z51.jpg GRAPHIC 28348
3 GRAPHIC g268475g95u36.jpg GRAPHIC 26780
4 GRAPHIC g268475pcpg01a.jpg GRAPHIC 32388
5 GRAPHIC g268475pcpg01b.jpg GRAPHIC 46699
6 GRAPHIC g268475pcpg01c.jpg GRAPHIC 8210
7 GRAPHIC g268475pcpg01d.jpg GRAPHIC 13932
8 GRAPHIC g268475pcpg01e.jpg GRAPHIC 36085
  Complete submission text file 0001193125-16-760234.txt   618649
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36304 | Film No.: 161975588
SIC: 2834 Pharmaceutical Preparations